Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individual Patient Expanded Access-Glembatumumab Vedotin

NCT03067935 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT03067935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03067935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individual Patient Expanded Access-Glembatumumab Vedotin
Lead sponsor
Celldex Therapeutics
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gpnmb expressing triple negative breast cancer